Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study.

Details

Ressource 1Download: Hodel F_Clinical Trasl Sc-Prevalence of actionable pharmacogenetic variants and high‐risk drug.pdf (209.46 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_1F053E42785D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study.
Journal
Clinical and translational science
Author(s)
Hodel F., De Min M.B., Thorball C.W., Redin C., Vollenweider P., Girardin F., Fellay J.
ISSN
1752-8062 (Electronic)
ISSN-L
1752-8054
Publication state
Published
Issued date
09/2024
Peer-reviewed
Oui
Volume
17
Number
9
Pages
e70009
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Drug type and dosing recommendation have been designed and optimized based on average response in the general population. Yet, there is significant inter-individual variability in drug response, which results in treatment inefficacy or adverse drug reactions in a subset of patients. This is partly due to genetic factors that typically affect drug metabolism or clearance. To verify the relevance and applicability of international pharmacogenetic guidelines in the Swiss population, we genotyped 1533 patients from a hospital-based biobank who received at least 30 different drugs, as documented in their electronic health record. We then assessed the prevalence of clinically actionable variants in 13 high-risk pharmacogenes. We compared the allele frequencies obtained in the hospital-based cohort with those of a Swiss population-based cohort of 4791 individuals. The prevalence of clinically actionable variants was comparable between the two cohorts, with most study participants (97.3%) carrying at least one actionable pharmacogenetic variant. We then assessed the frequency of high-risk prescriptions due to actionable gene-drug interactions and observed that 31% of patients in the hospital-based cohort were prescribed at least one drug for which they carried a high-risk variant, and for which international guidelines recommend a change of drug or dosage. Our analysis confirms the high prevalence of actionable pharmacogenetic variants in the Swiss population. It also shows that a substantial minority of patients are exposed to drugs for which they carry potentially problematic variants. Implementing a genetically informed approach to drug prescribing could have a positive impact on the quality of healthcare delivery.
Keywords
Humans, Switzerland, Female, Male, Pharmacogenomic Variants, Aged, Middle Aged, Cohort Studies, Gene Frequency, Adult, Drug Prescriptions/statistics & numerical data, Pharmacogenetics, Aged, 80 and over, Prevalence, Drug-Related Side Effects and Adverse Reactions/epidemiology, Drug-Related Side Effects and Adverse Reactions/genetics, Drug-Related Side Effects and Adverse Reactions/prevention & control
Pubmed
Web of science
Open Access
Yes
Create date
13/09/2024 11:36
Last modification date
20/09/2024 13:30
Usage data